Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Quinlan Amy 2. Date of Event Requiring Statement (Month/Day/Year) 05/08/2026 3. Issuer Name and Ticker or Trading Symbol Voyager Therapeutics, Inc. [VYGR] (Last) (First) (Middle) C/O VOYAGER THERAPEUTICS, INC.,, 75 HAYDEN AVENUE 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Principal Accounting Officer 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) LEXINGTON, MA 02421 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 36,749(1) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	01/13/2035	Common Stock	50,000	$5.28	D
Stock Option (Right to Buy)	(3)	02/06/2036	Common Stock	28,500	$3.68	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Quinlan Amy C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE LEXINGTON, MA 02421			Principal Accounting Officer

Signatures

/s/ Gregory L. Shiferman, as Attorney-in-Fact for Amy Quinlan		05/18/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Includes shares of common stock issuable under restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "2015 Plan") and the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan") that vest periodically. Each RSU represents the right to receive one share of common stock upon vesting.
(2)	This stock option was issued pursuant to the 2015 Plan. The vesting commencement date of the option is the grant date, January 13, 2025. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting on the one-year anniversary of the vesting commencement date, and an additional 1/36th of the shares of common stock underlying the option vesting monthly thereafter, subject to the Reporting Person's continued service.
(3)	This stock option was issued pursuant to the 2025 Plan. The vesting commencement date of the option is the grant date, February 06, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting on the first month anniversary of the vesting commencement date, and an additional 1/48th of shares underlying the option vesting monthly thereafter, subject to the Reporting Person's continued service.
Remarks: Exhibit 24.1: Limited Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.